Clinical Trial: Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261579) titled 'Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.' on Nov. 22.

Brief Summary: Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition marked by disturbed levels of various hematological inflammatory cells and a deregulated immune environment. While C-reactive protein (CRP) is a key acute-phase reactant, its high levels can persist even after inflammation subsides. Other simple, cost-effective ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), and Albumin-related ratios, also serve as promising, reproducible markers of systemic inflammation reflecting both im...